Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence. Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control;...

Full description

Saved in:
Bibliographic Details
Published inPatient preference and adherence Vol. 10; pp. 1299 - 1307
Main Authors Polonsky, William, Henry, Robert
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2016
Dove Medical Press
Subjects
Ambulatory care
California
Diabetes therapy
Drug delivery systems
Drugs
Emergency medical services
Glycosylated hemoglobin
Health aspects
Liraglutide
Medical personnel
Morbidity
Mortality
Patient compliance
Review
Type 2 diabetes
California
psychosocial
type 2 diabetes
medication adherence
glycemic control
HbA1c
hypoglycemia
Online AccessGet full text

Cover

More Information
Summary:At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence. Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes. Poor medication adherence is linked to key nonpatient factors (eg, lack of integrated care in many health care systems and clinical inertia among health care professionals), patient demographic factors (eg, young age, low education level, and low income level), critical patient beliefs about their medications (eg, perceived treatment inefficacy), and perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia). Specific barriers to medication adherence in T2D, especially those that are potentially modifiable, need to be more clearly identified; strategies that target poor adherence should focus on reducing medication burden and addressing negative medication beliefs of patients. Solutions to these problems would require behavioral innovations as well as new methods and modes of drug delivery.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1177-889X
1177-889X
DOI:10.2147/PPA.S106821